Title: Kidneyintelx Test Enhances SGLT2 Inhibitors Use in Diabetic Kidney Disease Treatment
Publication Date: April 23, 2025
Recent data from a study has shown a marked increase in the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors among patients at risk of diabetic kidney disease, who were tested with Renalytix plc’s Kidneyintelx biomarker-based prognostic test. The Kidneyintelx test was successfully used in identifying an expanded patient population who could benefit from the treatment, compared to the untested patients.
Renalytix plc is a company that leverages advanced diagnostics through artificial intelligence to deliver personalized kidney disease management and risk stratification. Its Kidneyintelx prognostic test aids in effectively targeting treatment with SGLT2 inhibitors to patients who are most likely to benefit. SGLT2 inhibitors, a class of prescription medicines approved for adults with type 2 diabetes, work by reducing glucose reabsorption in the kidney, resulting in less glucose in the bloodstream.
This development indicates a progressive growth in precision medicine, where the application of diagnostic tests like Kidneyintelx facilitates better targeting of therapies. Kidneyintelx enhances physician confidence in prescribing SGLT2 inhibitors by providing critical information about the patient’s disease progression, thus leading to improved patient outcomes.
Furthermore, the increase in the use of SGLT2 inhibitors based on the test results shows the potential of Kidneyintelx for broad adoption in managing diabetic kidney disease. It also enhances Renalytix’s product portfolio and market reach.
The implications of this development are substantial for investors in Renalytix plc. The successful study and increased use of Kidneyintelx test could lead to higher demand for the diagnostic and therefore increased revenues for the company. Juxtaposed against the backdrop of relentless rise in kidney diseases, particularly among the diabetic population, the market potential for such forward-looking diagnostic products is massive.
Keep abreast with Industry Informant for invaluable insights in the biotech market landscape, as we continue to provide pragmatic perspectives on significant industry developments.
